Merck (MRK) PT Lowered to $96 at BMO Capital as 'Gardasil Cut Lowers Confidence'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Merck (NYSE: MRK) to $96.00 (from $105.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
